Relativt få patienter inkluderet i fase III- studiet var < 5 år postmenopausalt og mellem 45 og 54 år (2 – 3%).
Relatively few patients less than 5 years postmenopausal and 45-54 years of age were enrolled in the phase III study (2-3%).